John Buse
#40,265
Most Influential Person Now
American academic
John Buse's AcademicInfluence.com Rankings
John Busemedical Degrees
Medical
#704
World Rank
#933
Historical Rank
#255
USA Rank
Epidemiology
#143
World Rank
#155
Historical Rank
#34
USA Rank
John Busephilosophy Degrees
Philosophy
#3622
World Rank
#5821
Historical Rank
#1134
USA Rank
Logic
#1307
World Rank
#2024
Historical Rank
#398
USA Rank
Download Badge
Medical Philosophy
John Buse's Degrees
- Doctorate Medicine University of Pennsylvania
- PhD Epidemiology University of North Carolina at Chapel Hill
Why Is John Buse Influential?
(Suggest an Edit or Addition)According to Wikipedia, John B. Buse is the Verne S. Caviness Distinguished Professor of Medicine at the University of North Carolina School of Medicine . He is also the director of UNC's Diabetes Care Center and the North Carolina Translational and Clinical Sciences Institute. In 2008, he held the position of President, Medicine & Science on the board of the American Diabetes Association .
John Buse's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of intensive glucose lowering in type 2 diabetes. (2008) (4946)
- Follow-up report on the diagnosis of diabetes mellitus. (2003) (3690)
- Effects of intensive blood-pressure control in type 2 diabetes mellitus. (2010) (3094)
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2014) (2714)
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. (2016) (2621)
- International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes (2009) (2534)
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) (2459)
- Effects of combination lipid therapy in type 2 diabetes mellitus. (2010) (2425)
- The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. (2005) (2400)
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2018) (2233)
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach (2012) (1934)
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. (2015) (1907)
- Strategies for multivessel revascularization in patients with diabetes. (2012) (1569)
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) (2009) (1429)
- Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. (2004) (1339)
- Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (2017) (1265)
- Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials (2009) (1158)
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2018) (1047)
- Long-term effects of intensive glucose lowering on cardiovascular outcomes. (2011) (950)
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study (2008) (944)
- How Do We Define Cure of Diabetes? (2009) (896)
- The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study (2010) (868)
- Molecular Biology of Mammalian Glucose Transporters (1990) (846)
- Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association (2006) (831)
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) (2009) (807)
- A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia (2005) (804)
- Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. (2010) (803)
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2019) (767)
- Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. (2008) (730)
- The prevention or delay of type 2 diabetes. (2002) (727)
- Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2015) (654)
- Effect of valsartan on the incidence of diabetes and cardiovascular events. (2010) (626)
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition (2015) (620)
- The metabolic syndrome: time for a critical appraisal (2005) (597)
- Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus (2007) (587)
- Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. (2003) (574)
- Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery (2015) (557)
- Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. (2002) (556)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. (2007) (530)
- Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes (2011) (509)
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study (2013) (501)
- Liraglutide and Renal Outcomes in Type 2 Diabetes (2017) (495)
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. (2016) (488)
- The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex. (1986) (441)
- Effect of nateglinide on the incidence of diabetes and cardiovascular events. (2010) (440)
- 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2019) (438)
- Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin-responsive tissues. (1989) (435)
- Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes (2017) (424)
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. (2017) (415)
- Correction to: 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD) (2020) (413)
- Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial (2010) (409)
- Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2008) (385)
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial (2012) (369)
- Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement (2007) (334)
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. (2015) (332)
- Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. (2005) (329)
- Recommendations for Management of Diabetes During Ramadan (2010) (318)
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks (2010) (318)
- Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum (2017) (314)
- 5. Prevention or Delay of Type 2 Diabetes (2016) (311)
- Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230)) (2010) (301)
- Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits (2010) (297)
- Recommendations for management of diabetes during Ramadan. (2005) (290)
- Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. (2007) (279)
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. (2014) (274)
- Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis (2010) (266)
- Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes (2017) (259)
- The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies (2015) (251)
- Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs (2020) (237)
- Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. (2007) (234)
- Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) (2014) (222)
- Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial (2014) (221)
- Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) (2013) (212)
- H2O2-Responsive Vesicles Integrated with Transcutaneous Patches for Glucose-Mediated Insulin Delivery. (2017) (211)
- Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. (2009) (200)
- Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. (2013) (200)
- Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. (2008) (196)
- Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. (2016) (195)
- A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. (2003) (189)
- International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors (2019) (183)
- Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial (2017) (180)
- Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents (2010) (178)
- Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes (2015) (174)
- Hypoxia and H2O2 Dual-Sensitive Vesicles for Enhanced Glucose-Responsive Insulin Delivery. (2017) (174)
- Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. (2003) (170)
- A Real-World Approach to Insulin Therapy in Primary Care Practice (2005) (166)
- Development and validation of the Diabetes Numeracy Test (DNT) (2008) (161)
- Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). (2022) (161)
- Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. (2016) (160)
- Advances in transdermal insulin delivery. (2019) (158)
- Core-Shell Microneedle Gel for Self-Regulated Insulin Delivery. (2018) (158)
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. (2016) (157)
- Human intestinal glucose transporter expression and localization of GLUT5. (1992) (155)
- Microneedles Integrated with Pancreatic Cells and Synthetic Glucose‐Signal Amplifiers for Smart Insulin Delivery (2016) (154)
- The safety of incretin-based therapies--review of the scientific evidence. (2011) (151)
- Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D) (2018) (150)
- Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes (2016) (148)
- Personalized Management of Hyperglycemia in Type 2 Diabetes (2013) (139)
- Small intestine hexose transport in experimental diabetes. Increased transporter mRNA and protein expression in enterocytes. (1994) (137)
- Correction to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2019) (136)
- Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study (2018) (135)
- Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters (2020) (133)
- Endothelial Dysfunction: Associations with Exposure to Ambient Fine Particles in Diabetic Individuals (2008) (132)
- Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. (2011) (132)
- DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results (2009) (127)
- Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2) (2017) (125)
- Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. (2019) (124)
- Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial (2019) (123)
- The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial (2015) (123)
- Synthetic beta cells for fusion-mediated dynamic insulin secretion. (2018) (122)
- One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial (2015) (119)
- Red Blood Cells for Glucose‐Responsive Insulin Delivery (2017) (118)
- Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies (2011) (117)
- DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality (2017) (116)
- Glucose Self-monitoring in Non–Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial (2017) (114)
- Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants (2012) (113)
- Bio-Inspired Synthetic Nanovesicles for Glucose-Responsive Release of Insulin (2014) (113)
- Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial (2016) (113)
- Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. (2014) (113)
- Glucose‐Responsive Insulin and Delivery Systems: Innovation and Translation (2019) (111)
- Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8+ T Cells in Type 1 Diabetes (2013) (110)
- Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes (2015) (110)
- Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum (2016) (109)
- Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes (2017) (108)
- Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study (2018) (108)
- Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus ( LEAD-4 Met + TZD ) (2009) (103)
- Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme (2013) (102)
- Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8 + T cells in type 1 diabetes (2014) (98)
- Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. (2021) (96)
- Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. (2002) (96)
- Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT-4) in patients with common-type non-insulin-dependent diabetes mellitus. (1991) (93)
- Bioresponsive Microneedles with a Sheath Structure for H2 O2 and pH Cascade-Triggered Insulin Delivery. (2018) (93)
- Two genes required for diabetes in BB rats. Evidence from cyclical intercrosses and backcrosses (1984) (92)
- Consensus statement on the worldwide standardisation of the HbA 1c measurement: The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation (2007) (92)
- Muraglitazar, a dual (α/γ) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes (2005) (91)
- COVID-19, Hyperglycemia, and New-Onset Diabetes (2021) (89)
- Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals (2010) (89)
- The DURABLE trial 24-week results (2008) (87)
- Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial (2013) (86)
- Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. (2016) (85)
- We Can Change the Natural History of Type 2 Diabetes (2014) (84)
- Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials (2016) (83)
- Troglitazone Use in Insulin-Treated Type 2 Diabetic Patients (1998) (83)
- Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study (2011) (82)
- Chronic Exposure to Arsenic and Markers of Cardiometabolic Risk: A Cross-Sectional Study in Chihuahua, Mexico (2015) (82)
- COVID-19 in People With Diabetes: Urgently Needed Lessons From Early Reports (2020) (80)
- Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5 (2015) (78)
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) (77)
- Charge-switchable polymeric complex for glucose-responsive insulin delivery in mice and pigs (2019) (76)
- Postprandial blood glucose. American Diabetes Association. (2001) (75)
- Combining insulin and oral agents. (2000) (74)
- Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience (2018) (74)
- Molecular Scanning of Insulin-Responsive Glucose Transporter (GLUT4) Gene in NIDDM Subjects (1991) (73)
- Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. (2020) (71)
- Erratum. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020;43:487–493 (2020) (71)
- Expression and regulation of the human GLUT4/muscle-fat facilitative glucose transporter gene in transgenic mice. (1992) (69)
- Inpatient Transition to Virtual Care During COVID-19 Pandemic. (2020) (69)
- Dipeptidyl‐peptidase‐4 inhibitors and pancreatic cancer: a cohort study (2014) (68)
- Sensor-augmented pump therapy for A1C reduction (STAR 3) study: Results from the 6-month continuation phase (2013) (68)
- Exploring salivary proteomes in edentulous patients with type 2 diabetes. (2012) (68)
- The GENNID Study: A resource for mapping the genes that cause NIDDM (1996) (68)
- Amylin Replacement With Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy (2002) (67)
- Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes (2012) (66)
- Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke: Post Hoc Analysis From the LEADER Trial (2018) (66)
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol. (2018) (64)
- Hormonal/metabolic regulation of the human GLUT4/muscle-fat facilitative glucose transporter gene in transgenic mice. (1993) (64)
- Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management (2014) (63)
- The insulin resistance syndrome and coronary artery disease (2003) (63)
- Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial (2017) (62)
- Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial (2020) (62)
- Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. (2018) (61)
- Diabetes Screening With Hemoglobin A1c Versus Fasting Plasma Glucose in a Multiethnic Middle-School Cohort (2013) (60)
- Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP) (2009) (59)
- CHAPTER 31 – Type 2 Diabetes Mellitus (2011) (59)
- The metabolic syndrome. (2005) (58)
- Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. (2022) (58)
- The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial (2018) (58)
- Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience (2012) (57)
- Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. (2016) (56)
- Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial (2017) (56)
- Glitazones and heart failure: critical appraisal for the clinician. (2003) (55)
- Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype (2018) (55)
- Human GLUT4/Muscle-Fat Glucose-Transporter Gene: Characterization and Genetic Variation (1992) (54)
- Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial (2017) (54)
- LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes (2014) (53)
- Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example (2019) (53)
- Associations between Arsenic Species in Exfoliated Urothelial Cells and Prevalence of Diabetes among Residents of Chihuahua, Mexico (2014) (51)
- Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin (2013) (49)
- Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program (2019) (49)
- INHIBITION OF GLUCOSE‐STIMULATED INSULIN RELEASE FROM βTC3 CELLS AND RODENT ISLETS BY AN ANALOG OF FK506 (1993) (48)
- Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years* (2008) (47)
- Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. (2010) (47)
- Screening for Diabetes and Prediabetes With Proposed A1C-Based Diagnostic Criteria (2010) (47)
- Pancreatic Safety of Sitagliptin in the TECOS Study (2016) (47)
- Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes (2017) (46)
- Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) (2017) (46)
- Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes* (2004) (45)
- Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. (2011) (45)
- Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide (2005) (44)
- Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial (2019) (44)
- Cardiovascular risk factors in multi‐ethnic middle school students: the HEALTHY primary prevention trial (2012) (43)
- Salivary proteins associated with hyperglycemia in diabetes: a proteomic analysis. (2013) (43)
- A survey of practices for the use of electronic health records to support research recruitment (2017) (42)
- Myeloid-derived suppressor cells are increased in frequency but not maximally suppressive in peripheral blood of Type 1 Diabetes Mellitus patients. (2014) (42)
- Metabolomic characteristics of arsenic-associated diabetes in a prospective cohort in Chihuahua, Mexico. (2015) (41)
- North Carolina internists' and endocrinologists' knowledge, opinions, and behaviors regarding periodontal disease and diabetes: need and opportunity for interprofessional education. (2011) (40)
- Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. (2005) (40)
- Dual self-regulated delivery of insulin and glucagon by a hybrid patch (2020) (39)
- Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. (2020) (39)
- Glucose-responsive oral insulin delivery for postprandial glycemic regulation (2018) (39)
- Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial (2017) (39)
- Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator (2019) (38)
- Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial (2018) (38)
- Insulin-Responsive Glucagon Delivery for Prevention of Hypoglycemia. (2017) (38)
- Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial (2016) (37)
- Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. (2013) (37)
- Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. (2012) (37)
- Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN‐6 cardiovascular outcomes trials (2020) (36)
- Statin Treatment in Diabetes Mellitus (2003) (36)
- Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial (2018) (35)
- Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes (2015) (35)
- Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy. (1999) (35)
- HLA-A2–Matched Peripheral Blood Mononuclear Cells From Type 1 Diabetic Patients, but Not Nondiabetic Donors, Transfer Insulitis to NOD-scid/γcnull/HLA-A2 Transgenic Mice Concurrent With the Expansion of Islet-Specific CD8+ T cells (2011) (35)
- Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. (2002) (34)
- Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial (2019) (34)
- Insulin Dose and Cardiovascular Mortality in the ACCORD Trial (2015) (34)
- Efficacy , Safety , and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes (2002) (34)
- Outpatient metformin use is associated with reduced severity of COVID‐19 disease in adults with overweight or obesity (2021) (33)
- Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial (2020) (33)
- Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study (2011) (33)
- 1643-P: Prevalence of Diabetes Medication Regimens in PCORnet, the National Patient-Centered Clinical Research Network (2019) (33)
- Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial (2019) (31)
- Lymphocyte abnormalities in the BB rat. (1983) (31)
- Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL (2019) (30)
- Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults (2018) (30)
- Diabetes educators' knowledge, opinions and behaviors regarding periodontal disease and diabetes. (2012) (29)
- Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. (2021) (29)
- Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial (2018) (29)
- Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes (2021) (28)
- The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial (2011) (28)
- Glucose transporter inhibitor-conjugated insulin mitigates hypoglycemia (2019) (28)
- The PROTECT Study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies. (1998) (28)
- Real-world evidence: the devil is in the detail (2020) (27)
- Sodium‐glucose co‐transporter‐2 inhibitor use and risk of lower‐extremity amputation: Evolving questions, evolving answers (2019) (27)
- Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes (2018) (27)
- Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial. (2019) (27)
- Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER (2021) (26)
- IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test (2015) (26)
- Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. (2018) (24)
- Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes (2018) (24)
- A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100 (2021) (24)
- Insulin glargine (HOE901): first responsibilities: understanding the data and ensuring safety. (2000) (23)
- Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial (2018) (23)
- Low rates of medical regimen change (2005) (23)
- Should postprandial glucose be routinely measured and treated to a particular target? No! (2003) (23)
- Low-density lipoprotein cholesterol versus particle number in middle school children. (2013) (23)
- Cardiometabolic Risk Assessments by Body Mass Index z-Score or Waist-to-Height Ratio in a Multiethnic Sample of Sixth-Graders (2014) (23)
- The trials and tribulations of determining HbA1c targets for diabetes mellitus (2020) (23)
- Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications (2004) (23)
- Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials (2020) (22)
- Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. (2018) (22)
- Type 1 Diabetes Mellitus (2011) (22)
- Effect of the GLP-1 Analog Liraglutide on Glycemic Control and Weight Reduction in Patients on Metformin and Rosiglitazone: a Randomized Double-Blind Placebo- Controlled Trial. (2008) (22)
- The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. (2014) (21)
- Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome (2018) (21)
- Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. (2019) (21)
- Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer. (2020) (20)
- Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). (2018) (20)
- BMI change, fitness change and cardiometabolic risk factors among 8th grade youth. (2013) (20)
- Liraglutide and Glycaemic Outcomes in the LEADER Trial (2018) (20)
- Ambient PM2.5 Exposure Up-regulates the Expression of Costimulatory Receptors on Circulating Monocytes in Diabetic Individuals (2010) (19)
- Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial (2018) (19)
- Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials (2019) (19)
- Type 2 diabetes mellitus in 2010: Individualizing treatment targets in diabetes care (2011) (18)
- Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene (2020) (18)
- PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid (2020) (18)
- LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations (2015) (18)
- No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase‐4 inhibitors vs therapeutic alternatives (2017) (18)
- The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin (2021) (17)
- A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies (2019) (17)
- Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11) (2019) (17)
- Sodium–Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions (2017) (17)
- Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. (2018) (17)
- Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes (2018) (17)
- 1.1 IDegLira, a Novel Fixed Ratio Combination of Insulin Degludec and Liraglutide, is Efficacious and Safe in Subjects with Type 2 Diabetes: A Large, Randomized Phase 3 Trial (65-OR) (2013) (17)
- Developing Insulin Delivery Devices with Glucose Responsiveness. (2020) (17)
- Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes (2019) (16)
- Can the American Diabetes Association Have an Impact on Preventing and Treating the Diabetes Epidemic in 2007–2008? An Interview With the Incoming President (2007) (16)
- Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD (2017) (16)
- Injectable Biodegradable Polymeric Complex for Glucose-Responsive Insulin Delivery. (2021) (16)
- Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7) (2019) (16)
- A Mixed-Methods, Randomized Clinical Trial to Examine Feasibility of a Mindfulness-Based Stress Management and Diabetes Risk Reduction Intervention for African Americans with Prediabetes (2019) (15)
- Major histocompatibility complex restriction fragment length polymorphisms define three diabetogenic haplotypes in BB and BBN rats (1985) (15)
- Effect of Once‐Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial (2018) (15)
- Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes (2014) (15)
- Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience. (2011) (15)
- A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes* (2007) (14)
- Initial injectable therapy in type 2 diabetes: key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. (2019) (14)
- Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon. (2005) (14)
- Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women (2017) (14)
- Progressive use of medical therapies in type 2 diabetes (2001) (13)
- Management of Type 1 Diabetes With a Very Low–Carbohydrate Diet: A Word of Caution (2018) (13)
- Performance of a computable phenotype for identification of patients with diabetes within PCORnet: The Patient‐Centered Clinical Research Network (2019) (13)
- The metabolic syndrome (2005) (13)
- Specific Class II Histocompatibility Gene Polymorphism in BB Rats (1984) (13)
- Cystic fibrosis transmembrane regulator mRNA expression relative to ion-nutrient transport in spontaneously differentiating human intestinal CaCo-2 epithelial cells. (1991) (13)
- Cardiovascular safety of the glucagon‐like peptide‐1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta‐analysis of randomized controlled trials (2015) (13)
- The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes (2021) (13)
- Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial (2017) (12)
- Supplementary Materials for Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8 + T Cells in Type 1 Diabetes (2013) (12)
- Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) (2022) (12)
- The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials (2020) (12)
- Novel measures of inflammation and insulin resistance are related to obesity and fitness in a diverse sample of 11–14 year-olds: The HEALTHY Study (2016) (12)
- Calendar time as an instrumental variable in assessing the risk of heart failure with antihyperglycemic drugs (2018) (12)
- Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis (2021) (12)
- Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System (2018) (12)
- A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies (2016) (12)
- Management of glycemia in type 2 diabetes. (1998) (12)
- Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (2017) (12)
- Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial (2020) (12)
- Prevention and Treatment of Complications of Diabetes (2009) (11)
- Carbohydrate Intake Prior to Oral Glucose Tolerance Testing (2021) (11)
- The demise of islet allotransplantation in the United States: A call for an urgent regulatory update (2021) (11)
- A pharmacoepidemiological study of diabetes mellitus and antipsychotic treatment in the United States (2002) (11)
- Medications for type 2 diabetes: how will we be treating patients in 50 years? (2015) (11)
- Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial (2020) (11)
- Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors (2016) (11)
- Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) (2019) (11)
- LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ (2016) (10)
- The case for a role for postprandial glucose monitoring in diabetes management. (1998) (10)
- Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10) (2019) (10)
- Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. (2022) (10)
- DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK (2018) (10)
- Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results (2020) (10)
- The HEALTHY study: introduction (2009) (10)
- Bibliometrics approach to evaluating the research impact of CTSAs: A pilot study (2020) (10)
- The Demise of Islet Allotransplantation in the US: A Call for an Urgent Regulatory Update The "ISLETS FOR US" Collaborative. (2020) (10)
- Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials (2015) (9)
- Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16) (2019) (9)
- Clinical experience with continuous glucose monitoring in adults. (2009) (9)
- Liraglutide More Effectively Achieves a Composite Endpoint for A1C, SBP and Weight Change Than Other Diabetes Therapies (2009) (9)
- The use of insulin alone and in combination with oral agents in type 2 diabetes. (1999) (9)
- Re-engineering The Clinical Research Enterprise in Response to COVID-19: The Clinical Translational Science Award (CTSA) experience and proposed playbook for future pandemics (2021) (9)
- Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. (2022) (9)
- Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes (2020) (9)
- Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy. (2011) (9)
- Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. (2022) (9)
- Glycemic Targets in Diabetes Care: Emerging Clarity after Accord. (2015) (9)
- Polymorphism in exon 4a of the human GLUT4/ muscle-fat facilitative glucose transporter gene detected by SSCP. (1991) (8)
- Effect of Secular Trends on a Primary Prevention Trial: The HEALTHY Study Experience (2011) (8)
- Cardiovascular Effectiveness of Sodium‐Glucose Cotransporter 2 Inhibitors and Glucagon‐Like Peptide‐1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure (2022) (8)
- Longitudinal phenotypes of type 1 diabetes in youth based on weight and glycemia and their association with complications. (2019) (8)
- Diabetes medication regimens and patient clinical characteristics in the national patient‐centered clinical research network, PCORnet (2020) (8)
- Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials (2020) (8)
- Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration (2014) (7)
- Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes (2020) (7)
- Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH Insulin (2014) (7)
- Characterizing the weight-glycemia phenotypes of type 1 diabetes in youth and young adulthood (2020) (7)
- Effect of relative weight group change on nuclear magnetic resonance spectroscopy derived lipoprotein particle size and concentrations among adolescents. (2014) (7)
- Pioglitazone in the treatment of type 2 diabetes mellitus: U.S. clinical experience (2000) (7)
- Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes? (2018) (7)
- Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus (1996) (7)
- 985-P: Oral Semaglutide as Add-On to Insulin in T2D: PIONEER 8 (2019) (7)
- Sotaglif lozin , a Dual SGLT 1 and SGLT 2 Inhibitor , as Adjunct Therapy to Insulin in Type 1 Diabetes (2015) (7)
- Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial (2019) (7)
- Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence (2022) (7)
- Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE (2020) (7)
- Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting (2019) (6)
- Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1) (2018) (6)
- Disordered cellular immunity in type 1 diabetes of man and the BB rat (1982) (6)
- 23. Insulin Degludec/Liraglutide (IDegLira) Is Superior to Insulin Glargine (IG) in A1c Reduction, Risk of Hypoglycemia, and Weight Change: DUAL V Study (166-OR) (2015) (6)
- Causal role of frontal-midline theta in cognitive effort: a pilot study. (2021) (6)
- Implementation and Evaluation of Shared Medical Appointments for Type 2 Diabetes at a Free, Student-Run Clinic in Alamance County, North Carolina. (2018) (6)
- Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms (2022) (6)
- Random blood glucose levels in patients with schizophrenia treated with typical and atypical antipsychotic agents: An analysis of data from double-blind, randomized, controlled clinical trial (2001) (6)
- Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (2018) (6)
- Drug Delivery: Microneedles Integrated with Pancreatic Cells and Synthetic Glucose-Signal Amplifiers for Smart Insulin Delivery (Adv. Mater. 16/2016). (2016) (6)
- Comprehensive Pulmonary Safety Review of Inhaled Technosphere® Insulin in Patients with Diabetes Mellitus (2020) (6)
- Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses (2021) (6)
- Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase‐4 inhibitors: An analysis of Medicare claims data from 2007 to 2015 (2019) (6)
- Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE (2021) (5)
- Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD Trial. (2011) (5)
- Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure (2020) (5)
- Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up (2022) (5)
- Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome (2018) (5)
- GLP-1 receptor agonists and basal insulin in type 2 diabetes (2014) (5)
- Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12) (2020) (5)
- A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment (2021) (5)
- Insights Into Patients' Experience With Type 1 Diabetes: Exit Interviews From Phase III Studies of Sotagliflozin. (2019) (5)
- Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type‐2 diabetes (2019) (5)
- Primum Non Nocere: Refocusing Our Attention on Severe Hypoglycemia Prevention (2018) (5)
- Development of a hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE (2020) (5)
- Abstract 14806: The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Most Body Mass Index Categories in Type 2 Diabetes: Results of the LEADER and SUSTAIN 6 Trials (2018) (5)
- CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC Processes (2015) (5)
- Impact of SARS-CoV-2 vaccination and booster on COVID-19 symptom severity over time in the COVID-OUT trial (2022) (5)
- What we think and what we know. (2002) (5)
- 21-LB: Derived Time-in-Range Is Associated with MACE in T2D: Data from the DEVOTE Trial (2020) (5)
- FRONTLINE: DIABETES—SUPPLEMENTING EDUCATION AND QUALITY IMPROVEMENT IN FAMILY MEDICINE RESIDENCY TRAINING (2008) (4)
- FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER (2019) (4)
- The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults (2018) (4)
- Safety of Degludec versus Glargine in Type 2 Diabetes. (2017) (4)
- Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs. (2012) (4)
- Can We Become Victims of Our Own Success? (2009) (4)
- Characteristics and Delivery of Diabetes Shared Medical Appointments in North Carolina (2019) (4)
- Identifying individual risk rare variants using protein structure guided local tests (POINT) (2019) (4)
- Identification of clinically relevant dysglycemia phenotypes based on continuous glucose monitoring data from youth with type 1 diabetes and elevated hemoglobin A1c (2019) (4)
- Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial (2021) (4)
- Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon (2005) (4)
- Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults (2019) (4)
- Glycemic Control and Clinical Outcomes in U.S. Patients With COVID-19: Data From the National COVID Cohort Collaborative (N3C) Database. (2022) (4)
- Evidence supports prediabetes treatment (2019) (4)
- Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights From the EXSCEL Trial (2017) (4)
- Three approaches to glucose monitoring in non-insulin treated diabetes: a pragmatic randomized clinical trial protocol (2017) (4)
- FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) – A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER (2019) (4)
- EFFECT OF LIRAGLUTIDE ON CARDIOVASCULAR OUTCOMES IN ELDERLY PATIENTS IN THE LEADER TRIAL (2018) (4)
- Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care 2016;39:1186–1201 (2017) (3)
- Efficacy and Safety of Faster Aspart Compared with Insulin Aspart Both with Insulin Degludec in Adults with T1D (2018) (3)
- Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response (2016) (3)
- Efficacy of oral semaglutide according to diabetes duration: An exploratory subgroup analysis of the PIONEER trial programme (2021) (3)
- Abstracts of the EASD, Stockholm 2010 (2010) (3)
- Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry (2020) (3)
- Lipid Changes Associated with Diabetes Therapy (2003) (3)
- Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity? (2020) (3)
- Évaluation des effets cardiovasculaires du liraglutide : Conception et données de base de l’étude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®) (2015) (3)
- Evolution in the American Diabetes Association Standards of Care (2003) (3)
- Health Literacy, Glycemic Control, and Physician-Advised Glucose Self-Monitoring Use in Type 2 Diabetes (2018) (3)
- Diabetes and periodontal therapy. (2014) (3)
- Managing the risks and benefits of clinical research in response to a pandemic (2021) (3)
- Autoimmune endocrine disease. (1985) (3)
- Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium–Glucose Cotransporter 2 Inhibitor (2020) (3)
- Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome‐Wide Interaction Meta‐Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies (2021) (3)
- A dead heat: target normal glucose levels in the intensive care unit—but with caution (2008) (2)
- Simplici-T1—First Clinical Trial to Test Activation of Glucokinase as an Adjunctive Treatment for Type 1 Diabetes (2018) (2)
- More realistic power estimation for new user, active comparator studies: an empirical example (2016) (2)
- 100 years on: the impact of the discovery of insulin on clinical outcomes (2021) (2)
- Genome-wide association analysis of metabolic syndrome quantitative traits in the GENNID multiethnic family study (2021) (2)
- Consensus development conference on pramlintide in the management of type 1 and type 2 diabetes (2006) (2)
- T-cell antigen receptor alpha chain polymorphisms in insulin-dependent diabetes. (1988) (2)
- PATIENTS WITH DIABETES AND PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE EXSCEL TRIAL (2019) (2)
- Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DM—A Real-World Analysis of >700,000 U.S. Patients (2018) (2)
- Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide (2021) (2)
- Glucose‐Responsive Systems: Glucose‐Responsive Insulin and Delivery Systems: Innovation and Translation (Adv. Mater. 13/2020) (2020) (2)
- A new class of drug in the diabetes toolbox (2022) (2)
- Chronic Exposure to Arsenic and Cardiometabolic Risk a Cross-Sectional Study in Chihuahua, Mexico (2014) (2)
- Prototype of an evidence‐based tool to aid individualized treatment for type 2 diabetes (2021) (2)
- Liraglutide and Renal Outcomes in Type 2 Diabetes. (2017) (2)
- Response to Comment on Hempe et al. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. Diabetes Care 2015;38:1067–1074 (2015) (2)
- Class I, II and III major histocompatibility complex gene polymorphisms in BB rats (1984) (2)
- Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes (2021) (2)
- SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS (2019) (2)
- Islets Transplantation at a Crossroads - Need for Urgent Regulatory Update in the United States: Perspective Presented During the Scientific Sessions 2021 at the American Diabetes Association Congress (2022) (2)
- Evaluating a CTSA-funded pilot grant program (2020) (2)
- Positioning newer drugs in the management of type 2 diabetes. (2021) (2)
- Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100 (2021) (2)
- Health Literacy, Glycemic Control, and Physician-Advised Glucose Self-Monitoring Use in Type 2 Diabetes. (2018) (2)
- PDB43 PATIENT REPORTED OUTCOMES ARE SUPERIOR IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH LIRAGLUTIDE AS COMPARED TO EXENATIDE, WHEN ADDED TO METFORMIN, SULFONYLUREA OR BOTH (2009) (2)
- Metabolic state and gustatory perception shapes dynamic interplay between cortical excitability and motor response (2020) (2)
- Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2) (2018) (2)
- Impact of liraglutide on reaching target HbA1c without weight gain or hypoglycaemia, versus other T2D therapies (2009) (2)
- Bringing closure: towards achieving a better understanding of Israel (2019) (2)
- Orals (2014) (2)
- RISK OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES WITH AND WITHOUT PRIOR CARDIOVASCULAR EVENTS: RESULTS FROM THE LEADER TRIAL (2017) (2)
- 15. Recombinant human hyaluronidase pretreatment of CSII cannula sites provides comparable glycemic control with reduced hypoglycemia in T1DM compared to usual CSII (85-LB) (2014) (2)
- Efficacy and Safety of Once-Weekly Exenatide versus Daily Liraglutide in Subjects with T2DM (DURATION-6) (2011) (2)
- 983-P: Effect and Safety of Flexible Dose Adjustment with Oral Semaglutide vs. Sitagliptin in Type 2 Diabetes: PIONEER 7 (2019) (2)
- Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin Plus Insulin vs. Insulin Alone. (2020) (2)
- Roep Reducing Proinsulin-Specific CD 8 + T Cells in Type 1 Diabetes Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically (2013) (2)
- The War Is Not Yet Won (2017) (1)
- ResearchAssociation of cardiac and vascular changes with ambient PM 2 . 5 in diabetic individuals (2010) (1)
- Clinical Care Guidelines: Too Much of a Good Thing? (2010) (1)
- 6-LB: Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL (2019) (1)
- Abstract 15282: Individual Participant Meta Analysis of the Cardiovascular Safety of Taspoglutide Among Individuals with Diabetes (2012) (1)
- APPLYING REWIND CVD CRITERIA TO SUSTAIN 6 AND PIONEER 6: AN EXPLORATORY ANALYSIS OF CV OUTCOMES WITH SEMAGLUTIDE (2020) (1)
- The DURABLE Trial 24-week Results: Safety and Efficacy of Insulin Lispro Mix 75/25 Versus Insulin Glargine Added to Oral Antihyperglycemic Drugs in Patients with Type 2 Diabetes (2009) (1)
- Medically tailored meals for food insecurity and type 2 diabetes: Protocol for the food as medicine for diabetes (FAME-D) trial. (2022) (1)
- Experimental increase of blood glucose alters resting state EEG measures of excitation–inhibition balance (2021) (1)
- Further RISE’ing to the Challenge of Type 2 Diabetes in Youth (2021) (1)
- Arguments against the Requirement of a Biological License Application for Human Pancreatic Islets: The Position Statement of the Islets for US Collaborative Presented during the FDA Advisory Committee Meeting (2021) (1)
- Insulin analogues (2001) (1)
- Arsenic exposure and cardiometabolic risk in Chihuahua, Mexico (2016) (1)
- B‐vitamins influence arsenic metabolism in Mexico (2013) (1)
- Skin‐Interfaced Deep‐Tissue Sensing Patch via Microneedle Waveguides (2022) (1)
- Severe Hypoglycemia, Cardiovascular Outcomes and Death in LEADER (2017) (1)
- Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea (2017) (1)
- Should postprandial glucose be routinely measured and treated to a particular target? Connecting the two sides of the debate. (2003) (1)
- THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS LIRAGLUTIDE AND SEMAGLUTIDE IMPROVE CARDIOVASCULAR AND RENAL OUTCOMES ACROSS BASELINE BLOOD PRESSURE CATEGORIES: ANALYSIS OF LEADER AND SUSTAIN 6 (2018) (1)
- 17-LB: Antihyperglycemic Use in Hemodialysis-Dependent Kidney Failure (2022) (1)
- Maria Gordon Buse, MD: A Family Affair Through Six Decades of Diabetes Discovery (2016) (1)
- Current Therapy of Diabetes Mellitus (1998) (1)
- Reasons for Increases in Complications of Diabetes. (2019) (1)
- DETAILED DESCRIPTION OF MYOCARDIAL INFARCTIONS AND THE VARIOUS SUBTYPES IN THE LEADER TRIAL (2017) (1)
- The DURABLE trial 24-week results : Safety and efficacy of insulin lispro mix 25 vs. insulin glargine added to oral antihyperglycaemic agents (OHAs) in patients with type 2 diabetes (T2D) (2008) (1)
- Glucose transporters - molecular structure and function (1989) (1)
- The Impact of Metformin Use on the Cardiovascular Effects of DPP-4 Inhibitors: an Analysis of Medicare Claims Data 2007– 2015 (2019) (1)
- INCREASED RISK OF SEVERE HYPOGLYCEMIC EVENTS BEFORE AND AFTER CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES: VALIDATION OF A NOVEL CONCEPT (2019) (1)
- Digestive Disease Week and American Diabetes Association: Action to Control Cardiovascular Risk (ACCORD) Trial (2008) (1)
- Effect on Body Weight of Naltrexone/Bupropion in Overweight and Obese Participants with Cardiovascular Risk Factors in a Large Randomized Double-Blind Study (2017) (1)
- A Cross-Validated Targeted Maximum Likelihood Estimator for Data-Adaptive Experiment Selection Applied to the Augmentation of RCT Control Arms with External Data (2022) (1)
- 321-OR: A Genetic Locus on Chromosome 1p36 Associated with Cardiovascular Autonomic Neuropathy in Type 2 Diabetes (2019) (0)
- Back Cover Image, Volume 93, Number 7, July 2021 (2021) (0)
- Impact of Expanding Access to Continuous Glucose Monitoring Systems Among Insulin Users with Type 1 or Type 2 Diabetes. (2023) (0)
- Partial remission of diabetes mellitus (type 1 or type 2) (2020) (0)
- Diabetes and Prediabetes: Diagnosis and Treatment (2009) (0)
- Risk of Major Cardiovascular Events in Patients With Type 2 Diabetes With and Without Prior CV Events: Results From The LEADER Trial (2018) (0)
- University of Dundee Genetic Variants in CPA6 and PRPF31 are Associated with Variation in Response to Metformin in Individuals with Type 2 Diabetes Rotroff, (2018) (0)
- View 2 ( Measuring Control ) Consensus Statement : Postprandial Blood Glucose (0)
- PRE-CONFERENCE EDUCATIONAL SESSIONS (2015) (0)
- Consensus Reports (2011) (0)
- Exposure to arsenic and cardiometabolic risk in Chihuahua, Mexico (2014) (0)
- Study Design Choices for Evaluating Comparative Safety of Diabetic Medications: An Evaluation of Pioglitazone and Bladder Cancer Risk Among Older US Adults with Type-2 Diabetes (2020) (0)
- P2858Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial (2018) (0)
- Up Front (2018) (0)
- Effect of Glucose Monitoring on Patient and Provider Outcomes in Non-Insulin Treated Diabetes (2018) (0)
- Salivary Metabolomics of Well and Poorly Controlled Type 1 and Type 2 Diabetes (2022) (0)
- 122-LB: The Simplici-T1 Trial: Glucokinase Activator TTP399 Improves Glycemic Control in Patients with Type 1 Diabetes (2020) (0)
- Clinical and Metabolic Characterization of Adults With Type 2 Diabetes by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) Cohort (2022) (0)
- Elevated Cardiometabolic Risk by Chronic Inorganic Arsenic Exposure in Chihuahua, Mexico. (2014) (0)
- 1141-P: Detailed Phenotype of Randomized Participants by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) (2019) (0)
- Changes in serum calcitonin concentrations and incidence of adjudicated medullary thyroid carcinoma in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) (2018) (0)
- Exenatide and GLP-1: Novel Treatments for Type 2 Diabetes (2005) (0)
- Potential impact of differential drop-in of open-label diabetes medications in EXSCEL (2018) (0)
- Late-Breaking Clinical Trial Report (2011) (0)
- Panel discussion on achieving glycemic control. (2001) (0)
- Are fewer cases of diabetes mellitus diagnosed in the months after SARS-CoV-2 infection? A population-level view in the EHR-based RECOVER program (2023) (0)
- Enrollment of underrepresented racial and ethnic groups in the Rare and Atypical Diabetes Network (RADIANT) (2023) (0)
- Are fewer cases of diabetes mellitus diagnosed in the months after SARS-CoV-2 infection? (2022) (0)
- Achieving glycaemic control and weight loss with incretin-based therapies: a comparison of liraglutide, exenatide, and sitagliptin (2011) (0)
- Treatment of postprandial hyperglycemia in type 2 diabetes. (2001) (0)
- Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs (2020) (0)
- Scintillation Scanning of Kidneys (2020) (0)
- ESICON 2019 Abstracts (2019) (0)
- 117 - Diabetes Duration Did Not Moderate Severe Hypoglycemia Seen With Glargine U100 vs Degludec in DEVOTE (2019) (0)
- 65-LB: Real-World Continuous Glucose Monitoring Data on Time-in-Range from a U.S. Population, 2015–2019 (2021) (0)
- Author response for "Study Design Choices for Evaluating Comparative Safety of Diabetic Medications: An Evaluation of Pioglitazone and Bladder Cancer Risk Among Older US Adults with Type‐2 Diabetes" (2019) (0)
- Identifying individual risk rare variants using protein structure-guided local tests (POINT) (2018) (0)
- Abstract 15589: Mitochondrial Metabolites Predict Cardiovascular Outcomes and Heart Failure in People With Type 2 Diabetes Mellitus and Vascular Disease: A Tecos Substudy (2020) (0)
- Complete remission of diabetes mellitus (type 1 or type 2) (2020) (0)
- Thiazolidinediones in the treatment of type 2 diabetes: a clinician's perspective. (2000) (0)
- Increased Derived Time in Range is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE. (2023) (0)
- Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL, a randomized trial, design and baseline characteristics. (2023) (0)
- Researchof cardiac and vascular changes with ambient PM 2.5 in diabetic individuals (2010) (0)
- Type i diabetes mellitus chronic progressive autoimmune beta cell destruction (1985) (0)
- Arsenic Exposure and Impaired Glucose Homeostasis: Adequate vs Elevated Folate Intake (2016) (0)
- LIRAGLUTIDE REDUCES CARDIOVASCULAR EVENTS AND MORTALITY IN TYPE 2 DIABETES INDEPENDENT OF LDL CHOLESTEROL AND STATIN USE: RESULTS OF THE LEADER TRIAL (2018) (0)
- Diabetes medications and associations with Covid-19 outcomes in the N3C database: A national retrospective cohort study (2022) (0)
- Latest Developments in Continuous Glucose Monitoring, Insulin, and Adjunctive Treatments in Type 1 Diabetes (2018) (0)
- Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. Reply. (2022) (0)
- The Cancer-Insulin Link: Where We Stand Today (2012) (0)
- A Special Thanks to the Reviewers of Diabetes Care (2017) (0)
- 68 Metformin prevents the diagnosis of Long Covid in phase 3 trial of early treatment. (2023) (0)
- Abstract 4: Derived time-in-range is associated with major adverse cardiovascular event in T2D: Data from the DEVOTE trial (2022) (0)
- Drug Delivery Devices: Insulin-Responsive Glucagon Delivery for Prevention of Hypoglycemia (Small 19/2017) (2017) (0)
- A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes (2018) (0)
- IMPACT OF MICROVASCULAR DISEASE ON CARDIORENAL OUTCOMES IN TYPE 2 DIABETES: AN ANALYSIS FROM THE LEADER AND SUSTAIN-6 CLINICAL TRIALS (2019) (0)
- Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes (2022) (0)
- THE EFFECTS OF THIAZOLIDINEDIONE AND BIGUANIDE COMBINATION THERAPY ON SERUM LIPID CONCENTRATIONS AND GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES (2002) (0)
- Resource use and UK-perspective costs in patients with type 2 diabetes during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (2017) (0)
- The DURABLE Trial : comparing durability of lispro mix 25 vs glargine (2010) (0)
- 88 - Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: LEADER and SUSTAIN 6 (2019) (0)
- Skin‐Interfaced Deep‐Tissue Sensing Patch via Microneedle Waveguides (Adv. Mater. Technol. 9/2022) (2022) (0)
- Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors (2016) (0)
- Effect of relative weight group change on NMR spectroscopy derived lipid particle size and concentrations among adolescents (2014) (0)
- Professional Practice Committee Members (2011) (0)
- Author response for "Prototype of an evidence‐based tool to aid individualized treatment for type 2 diabetes" (2021) (0)
- High insulin levels: Target for treatment? (2001) (0)
- Pancreatic Safety of Sitagliptin in the TECOS Trial (2017) (0)
- Synthetic β-cells for fusion-mediated dynamic insulin secretion (2017) (0)
- Diabetic genetics: A complex picture (2002) (0)
- Efficacy of sotagliflozin 400 mg/day in 1402 patients with type 1 diabetes treated with any insulin regimen (inTandem 3) (2018) (0)
- Rede fi ning Hypoglycemia in Clinical Trials: Validation of De fi nitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes (2020) (0)
- The Art of Diabetes Care. (2023) (0)
- Linking Clinical Care and Community Interventions in Diabetes Prevention and Management (2013) (0)
- 123-LB: The Simplici-T1 Trial: Relationship between Glycemic Control and Insulin Dose (2020) (0)
- Statement of the American Diabetes Association and a Scientific Statement of the Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Intensive Glycemic Control and the Prevention of Cardiovascular Events: (2009) (0)
- 2160-PUB: Development of an Evidence-Based Tool to Facilitate Individualized Treatment in the Clinic for Patients with Type 2 Diabetes (2020) (0)
- Remission of diabetes mellitus (type 1 or type 2) (2020) (0)
- Retrospective analysis of risk factors in patients Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical with treatment-emergent diabetes during clinical trials of antipsychotic medications trials of antipsychotic medications (2005) (0)
- The Endocrine Pancreas (2020) (0)
- Safety of Degludec versus Glargine in Type 2 Diabetes. (2017) (0)
- Antihyperglycemic Medication Use Among U.S. Adults With Hemodialysis-Dependent Kidney Disease and Comorbid Diabetes. (2022) (0)
- 665-P: Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs. 1.0 mg by Baseline HbA1c and BMI: SUSTAIN FORTE Subgroup Analyses (2021) (0)
- Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes (2020) (0)
- Are “Hemochromatosis gene” mutations a risk factor for type 2 diabetes? (2001) (0)
- Adverse events in diabetes drug trial – Authors' reply (2009) (0)
- 4300 Evaluation and structure of the pilot funding program at the University of North Carolina CTSA Hub (NC TraCS) (2020) (0)
- 143-OR: Mapping Genetic Determinants of Blood Glucose Control in the Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD) (2022) (0)
- Erratum. Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care 2013;36:2254-2261. (2022) (0)
- 58 - Efficacy of Oral Semaglutide According to Background Medication: An Exploratory Subgroup Analysis of the PIONEER Trial Program (2020) (0)
- NEW THERAPIES IN TYPE 1 DIABETES Inflammatory markers are increased in youth with type 1 diabetes : the SEARCH case – control study (2011) (0)
- Engraftment of peripheral blood mononuclear cells from patients with type 1 diabetes in NOD-scid HLA-A*0201/{gamma}c -/-immunodeficient mice (2010) (0)
- "The Times They Are A-Changin'" at Diabetes Care. (2022) (0)
- Meet the Expert Sessions (2017) (0)
- Are prescribing patterns of antidiabetic medications influenced by fears of litigation? (2008) (0)
- Up front (2019) (0)
- 8-LB: Outcomes of Type 2 Diabetes (T2D) Clustering Replicated in the DEVOTE Trial (2019) (0)
- 21 - Effect and Safety of Flexible Dose Adjustment With Oral Semaglutide vs Sitagliptin in Type 2 Diabetes: PIONEER 7 (2019) (0)
- A Special Thanks to the Reviewers of Diabetes Care (2020) (0)
- Effect of SARS-CoV-2 Infection and Infection Severity on Longer-Term Glycemic Control and Weight in People With Type 2 Diabetes (2022) (0)
- Retrospective assessment of risk factors for treatment emergent glucose abnormalities during randomized, double-blind clinical trials of medications for treatment of schizophrenia (2003) (0)
- Exenatide for type 2 diabetes – Authors' reply (2009) (0)
- ESICON 2018 Abstracts (2018) (0)
- A method for comparing multiple imputation techniques: a case study on the U.S. National COVID Cohort Collaborative (2022) (0)
- ESICON 2019 Abstracts (2019) (0)
- Abstract 1182: High Frequency of Unrecognized Diabetes in Cardiovascular Patients: Should All Have an Oral Glucose Tolerance Test? (2008) (0)
- The Rare and Atypical Diabetes Network (RADIANT) Study: Design and Early Results. (2023) (0)
- ESICON 2017 Abstracts (2017) (0)
- ESICON 2019 Abstracts (2019) (0)
- Abstract 14727: Meteorin-like Glial Cell Differentiation Regulator is a Novel Protein Biomarker of Cardiovascular Outcomes in Patients With Diabetes and Vascular Disease: A TECOS Substudy (2020) (0)
- Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. (2020) (0)
- IMPACT OF MICROVASCULAR DISEASE ON CARDIORENAL OUTCOMES IN TYPE 2 DIABETES: AN ANALYSIS FROM THE LEADER AND SUSTAIN 6 CLINICAL TRIALS (2019) (0)
- Abstract 16033: A Paradoxical Relationship of Plasma Adiponectin to Cardiovascular Risk in Patients With Diabetes and Recent Acute Coronary Syndrome - the Alecardio Trial (2016) (0)
- Dipeptidyl Peptidase 4 Inhibitors and Risk of In fl ammatory Bowel Disease: Real-world Evidence in U.S. Adults (2019) (0)
- Chapter 1 – Scope of the Problem: The Diabetes and Metabolic Syndrome Epidemic (2006) (0)
- Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial (2023) (0)
- ESICON 2019 Abstracts (2019) (0)
- Abstract 11459: Mitochondrial Metabolites Predict Cardiovascular Outcomes and Heart Failure in Individuals with Type 2 Diabetes Mellitus: An Exscel Biomarker Substudy (2021) (0)
- Abstract P071: Moderate Exposure to Inorganic Arsenic in Drinking Water is Associated with Elevated Pulse Pressure: Results from Chihuahua, Mexico (2017) (0)
- Managing Dyslipidemia and Global Risk in Patients with Type 2 Diabetes and Insulin Resistance Managing Dyslipidemia and Global Risk in Patients with Type 2 Diabetes and Insulin Resistance (2005) (0)
- Abstract 15852: Treated Systolic Blood Pressure and Cardiovascular Risk in Adults With Hypertension and Type 2 Diabetes: Results From the TECOS Trial (2016) (0)
- Concerns About Conclusions of Self-monitoring of Blood Glucose-Reply. (2017) (0)
- 1116-P: Enrollment of Racial/Ethnic Minorities in the Rare and Atypical Diabetes Network (RADIANT) (2022) (0)
- Author response for "The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: analysis of LEADER and SUSTAIN 6 trials" (2020) (0)
- Author response for "Long‐term efficacy and safety of combined insulin and GLP‐1 therapy: evidence from the LEADER trial" (2019) (0)
- Reducing Bias in Academic Publishing: The Diabetes Care Approach. (2023) (0)
- 4299 The University of North Carolina CTSA Hub (NC TraCS) Service Evaluation: Using Customer Feedback to Improve Services (2020) (0)
- A war not yet won (2012) (0)
- P-1405 Glycaemic control improves in type 2 diabetes patients when switching from twice-daily exenatide to once-daily liraglutide (2009) (0)
- Liraglutide and Renal Outcomes in Type 2 Diabetes. (2017) (0)
- The DURABLE Trial (2010) (0)
- Questionnaire-Based Polyexposure Assessment Outperforms Polygenic Scores for Classification of Type 2 Diabetes in a Multiancestry Cohort (2022) (0)
- High Frequency of Unrecognized Diabetes in Cardiovascular Patients: Should All Have an Oral Glucose Tolerance Test? (2008) (0)
- 752-P: Study Design and Baseline Profile for Patients with Type 2 Diabetes in the Semaglutide Once-Weekly Randomized Pragmatic Trial (SEPRA) (2022) (0)
- Beyond the Cox Hazard Ratio: A Targeted Learning Approach to Survival Analysis in a Cardiovascular Outcome Trial Application (2023) (0)
- Engraftment of peripheral blood mononuclear cells from patients with type 1 diabetes in NOD-scid HLA-A*0201/γc -/-immunodeficient mice (93.5) (2010) (0)
- Glycemic Control with Fast-Acting Insulin Aspart According to Dose Adjustment Method in Type 1 Diabetes: A Post Hoc Analysis of Onset 8 (2018) (0)
- 101-OR: Efficacy and Safety of Once-Weekly Semaglutide 2.0 vs. 1.0 mg for Type 2 Diabetes: SUSTAIN FORTE Randomized Trial (2021) (0)
- The quality of care of very low birth weight babies in Brazil (2007) (0)
- 835-P: The Hepatoselective Glucokinase Activator (GKA) TTP399 Does Not Increase Risk of Ketoacidosis in Type 1 Diabetes (T1D) (2022) (0)
- chorego – stanowisko American Diabetes Association ( ADA ) i European Association for the Study of Diabetes ( EASD ) (2016) (0)
This paper list is powered by the following services:
Other Resources About John Buse
What Schools Are Affiliated With John Buse?
John Buse is affiliated with the following schools:
